| |
[摘要]：Poly(ADP-ribose)polymerase 1 (PARP-1) is an essential enzyme in the repair of single-strand breaks in DNA via the base excision repair pathway and has become an important novel target in cancer therapy. PARP inhibitors represent a major breakthrough for patients with hereditary BRCA-associated cancers as a promising new class of anticancer agents. This review will summarize PARP inhibition, including the mechanism of action, its role in the treatment of BRCA1- and 2-associated cancers, the promise of combination therapy with cytotoxic agents and future directions for PARP inhibition in the clinical setting. |
|
